Skip to main content

Table 3 Complications, Treatment, Outcome

From: Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study

 

All patients

(n = 319)

Discharged

(n = 238)

Deceased

(n = 81)

p-value

Treatment

 Hydroxychloroquine — no. (%)

164 (51.41)

130 (54.62)

34 (41.98)

0.0489

 Antibiotics — no. (%)

227/318 (71.38)

161/237 (67.93)

66/81 (81.48)

0.0164

 Systemic glucocorticoids — no. (%)

36/317 (11.36)

25/237 (10.55)

11/80 (13.75)

0.4436

 Mechanical ventilation — no. (%)

71 (22.26)

46 (19.33)

25 (30.86)

0.0354

   - Invasive ventilation

40 (12.54)

23 (9.66)

17 (20.99)

0.0112

   - Non-invasive ventilation

22 (6.90)

15 (6.30)

7 (8.64)

0.4830

   - High flow oxygen device

9 (2.82)

8 (3.36)

1 (1.23)

0.2779

Complications

 Acute respiratory distress syndrome — no. (%)

45 (14.11)

24 (10.08)

21 (25.93)

0.0008

 Acute kidney injuryc — no. (%)

57 (17.87)

20 (8.40)

37 (45.68)

< 0.0001

   - Need for renal replacement therapy

13 (4.08)

5 (2.10)

8 (9.88)

0.0049

 Venous thrombo-embolism — no. (%)

25 (7.84)

20 (8.40)

5 (6.17)

0.5088

   - Deep venous thrombosis

22 (6.90)

17 (7.14)

5 (6.17)

0.7634

   - Pulmonary embolism

5 (1.57)

3 (1.26)

2 (2.47)

0.3853†

 Hypoglycemiaa — no. (%)

16 (5.02)

9 (3.78)

7 (8.64)

0.1013

 Hyperglycemia b — no. (%)

22 (6.90)

12 (5.04)

10 (12.35)

0.0343

 Stroke — no. (%)

4 (1.25)

0 (0.00)

4 (4.94)

0.0021

 Hyponatraemia < 135 mmol/L — no. (%)

157 (49.22)

120 (50.42)

37 (45.68)

0.4607

 Hyponatraemia < 130 mmol/L — no. (%)

74 (23.20)

63 (26.47)

11 (13.58)

0.0133

Outcome

 Admission to the ICU — no. (%)

63 (19.75)

39 (16.39)

24 (29.36)

0.0123

 Median length of stay in hospital — no. (%)

8 (5–14)

8 (5–14)

8 (5–12)

0.0273

   - Not known

1

1

0

 
  1. aHypoglycemia was defined as a serum glucose level of < 70 mg/dl
  2. bHyperglycemia was defined as a serum glucose level of > 250 mg/dl
  3. cAcute kidney injury was defined according to the KDIGO guidelines as an increase in serum creatinine by 0.3 mg/dl within 48 h, or an increase in serum creatinin 1.5 times baseline creatinin, which is known or presumed to have occurred within the prior 7 days